Review



dnam 1 blocking antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    R&D Systems dnam 1 blocking antibody
    Dnam 1 Blocking Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dnam+1+blocking+antibody/Human+DNAM-1%2FCD226+Antibody/pmc06774869-115-1-6
    Average 91 stars, based on 1 article reviews
    dnam 1 blocking antibody - by Bioz Stars, 2026-10
    91/100 stars

    Images

    Related Articles

    other:

    Article Title: Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma
    Article Snippet: SLAMF7 expression was assayed by staining with biotinylated Elo conjugated antibody (EZ-Link NHS-Biotin, ThermoFisher #20217) and APC-streptavidin (Biolegend, #405207), SLAMF7 antibody conjugated with APC or DL650 (Biolegend, clone 162.1; ( 41 )), or isotype control (Biolegend, #400330).

    Article Title: Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma
    Article Snippet: Flow cytometry SLAMF7 expression was assayed by staining with biotinylated Elo conjugated antibody (EZ-Link NHS-Biotin, ThermoFisher #20217) and APC-streptavidin (Biolegend, #405207), SLAMF7 antibody conjugated with APC or DL650 (Biolegend, clone 162.1; ( 41 )), or isotype control (Biolegend, #400330).

    Blocking Assay:

    Article Title: Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
    Article Snippet: The m24 antibody targeting activated LFA-1 and NKG2D blocking antibody, 1D11, were from BioLegend. .. The DNAM-1 blocking antibody was from R&D Systems (AF666; polyclonal goat IgG). .. SLAMF7 expression was assayed by staining with biotin conjugated Elo antibody (EZ-Link NHS-Biotin, Thermo Fisher #20217) and APC–streptavidin (BioLegend, #405207), SLAMF7 antibody conjugated with APC or DL650 (BioLegend, clone 162.1; ref. 41), or isotype control (BioLegend, #400330).



    Similar Products

    blocking antibodies against dnam-1 (cd226)  (Thermo Fisher)
    90
    Thermo Fisher blocking antibodies against dnam-1 (cd226)
    Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against <t>CD226</t> and NKG2D, or isotype-matched control antibodies.
    Blocking Antibodies Against Dnam 1 (Cd226), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dnam+1+blocking+antibody/anti+mouse+cd226+functional+grade++clone++10e5+/pmc06658523-179-8-12
    Average 90 stars, based on 1 article reviews
    blocking antibodies against dnam-1 (cd226) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    dnam-1 blocking antibody clone dx11  (GeneTex)
    90
    GeneTex dnam-1 blocking antibody clone dx11
    Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against <t>CD226</t> and NKG2D, or isotype-matched control antibodies.
    Dnam 1 Blocking Antibody Clone Dx11, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dnam+1+blocking+antibody/cd226+blocking+antibody+dx11/pm40073261-38-0-8
    Average 90 stars, based on 1 article reviews
    dnam-1 blocking antibody clone dx11 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    dnam 1 blocking antibody  (R&D Systems)
    91
    R&D Systems dnam 1 blocking antibody
    Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against <t>CD226</t> and NKG2D, or isotype-matched control antibodies.
    Dnam 1 Blocking Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dnam+1+blocking+antibody/Human+DNAM-1%2FCD226+Antibody/pmc06774869-115-1-6
    Average 91 stars, based on 1 article reviews
    dnam 1 blocking antibody - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    blocking antibodies against human dnam 1  (R&D Systems)
    93
    R&D Systems blocking antibodies against human dnam 1
    Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against <t>CD226</t> and NKG2D, or isotype-matched control antibodies.
    Blocking Antibodies Against Human Dnam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dnam+1+blocking+antibody/Human+DNAM-1%2FCD226+Biotinylated+Antibody/pm26138671-58-4-12
    Average 93 stars, based on 1 article reviews
    blocking antibodies against human dnam 1 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against CD226 and NKG2D, or isotype-matched control antibodies.

    Journal: Scientific Reports

    Article Title: Natural killer cells impede the engraftment of cardiomyocytes derived from induced pluripotent stem cells in syngeneic mouse model

    doi: 10.1038/s41598-019-47134-3

    Figure Lengend Snippet: Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. ( A ) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( B ) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. ( C ) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. ( D ) Flow cytometric detection of MHC class II (I-A/I-E) molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. ( E ) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. ( F ) Flow cytometric detection of NK1.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK1.1 and CD3, or isotype-matched control antibodies. ( G ) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against CD226 and NKG2D, or isotype-matched control antibodies.

    Article Snippet: Cultured NKCs were washed and incubated with blocking antibodies against DNAM-1 (CD226) (Thermo Fisher Scientific) and NKG2D (BioLegend) for 90 min at room temperature.

    Techniques: Expressing, Purification, Control, Staining, Real-time Polymerase Chain Reaction, Cell Culture